Clinical Investigations – Research Article

Megna M.a· De Lucia M.a· Gallo L.a· Lauro W.a· Picone V.a· Fabbrocini G.a· Ocampo-Garza S.S.b

Author affiliations

aDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
bDermatology Department, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: September 11, 2022
Accepted: November 04, 2022
Published online: December 08, 2022

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Abstract

Introduction: Psoriatic alopecia is considered a type of hair loss occurring in patients with psoriasis. Adalimumab is a fully humanized recombinant anti-TNF-alpha monoclonal antibody approved for treatment of psoriasis and psoriatic arthritis (PsA), rarely related to the occurrence of dermatological disorders. Case Presentation: We report the case of a 56-year-old female with PsA developing psoriatic alopecia and paradoxical psoriasis induced by adalimumab and successfully treated switching to certolizumab, evaluating response at both thrichoscopy and in vivo reflectance confocal microscopy. Discussion: Among anti-TNF-α agents, certolizumab is the least involved in the development of paradoxical reactions such as psoriatic alopecia and showed to be an effective and safe alternative therapeutic options to manage psoriasis and PsA minimizing the risk of paradoxical reactions.

© 2022 S. Karger AG, Basel

References Gerriets V, Bansal P, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. 2021 jul 18. StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016 Oct;138(4):984–1010. Epub 2016 Aug 28 Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005 Jul;4(4):637–41. George SM, Taylor MR, Farrant PB. Psoriatic alopecia. Clin Exp Dermatol. 2015 Oct;40(7):717–21. Epub 2015 Jul 23 Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr(Engl Ed). 2018;109(9):791–800. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012;30(5):700–6. Doyle LA, Sperling LC, Baksh S, Lackey J, Thomas B, Vleugels RA, et al. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011;33(2):161–6. Toda-Brito H, Lopes L, Soares-Almeida L, Filipe P. Adalimumab- induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn’s disease. Dermatol Online J. 2015;21(11). Loftus EV Jr, Colombel JF, Schreiber S, Randall CW, Regueiro M, Ali T, et al. Safety of long- term treatment with certolizumab pegol in patients with Crohn’s disease, based on a pooled analysis of data from clinical trials. Clin Gastroenterol Hepatol. 2016;14(12):1753–62. Béné J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P, et al. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014 Aug;53(8):1465–9. Aragón-Miguel R, Calleja-Algarra A, Vico-Alonso C, Sánchez-Velázquez A, Garrido MC, Ortiz-Romero PL, et al. Psoriatic alopecia-like paradoxical reaction to certolizumab pegol. Int J Dermatol. 2019 Jun;58(6):e118–e120. Epub2019 Mar 1 Ferraresso MG, Garlatti MLB, Perez-Chada LM, Martin MS, Mazzuoccolo LD. Certolizumab-induced paradoxical psoriatic alopecia. J Psoriasis Psoriatic Arthritis. 2020;5(3):86–92. Lauro W, Picone V, Abategiovanni L, Vastarella M, Gallo L, Fabbrocini G, et al. A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation. Int J Dermatol. 2022 May 17. Mihailescu M, Cibull T, Joyce J. Development of drug-induced psoriasiform alopecia in a pediatric patient on ustekinumab. J Cutan Pathol. 2021 Dec;48(12):1523–5. Epub 2021 Sep 1 Tan TL, Taglia L, Yazdan P. Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy. J Cutan Pathol. 2021 Jun;48(6):771–4. Epub 2021 Jan 12 Jeong KM, Seo JY, Kim A, Baek YS, Song HJ, Jeon J. Tumor necrosis factor-alpha inhibitor-associated psoriatic alopecia in a patient with ulcerative colitis: a case report and review of the literature. Ann Dermatol. 2021 Feb;33(1):82–5. Article / Publication Details

First-Page Preview

Received: September 11, 2022
Accepted: November 04, 2022
Published online: December 08, 2022

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.